Why the study?
Myocardial fibrosis is a common feature of heart disease with no approved therapeutic options, and the role of reversible fibroblast phenotypic switching in cardiac remodelling remained to be explored.
Fibroblast phenotypic switching between quiescent and activated states may serve as a central therapeutic target for counteracting adverse cardiac fibrosis.
Answers are grounded in this paper and cite their sources.
Fibroblast switching may be a fibrosis target in animals; leaves open translation to human therapies.
Myocardial fibrosis, a common feature of heart disease, remains an unsolved clinical challenge. Fibrosis resolution requires activation of cardiac fibroblasts exhibiting context-dependent beneficial and detrimental dichotomy. Here, we explored the hypothesis of fibroblast reversible transition between quiescence and activated myofibroblastic states as a manifestation of cell phenotypic switching in myocardial remodelling. In support, gene regulatory networks executing conversion of cardiac fibroblasts to myofibroblasts and vice versa in fibrosis resolution are reconstructed using TRANSPATH database. In a scenario of fibroblast activation triggered by transforming growth factor β, a cardinal mediator of tissue fibrosis, signalling cascades governing entry into or exit from specific fibroblast statures in cardiac fibrotic remodelling were dissected. It is suggested that fibroblast phenotypic switching constitutes the central gait toward guiding cell state-gating strategies to counteract adverse cardiac fibrosis, a devastating disorder with no approved therapeutic option.
No takes yet. Share an insight, caveat, or question.
Kel et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: